Citation Impact
Citing Papers
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Long‐term intraarterial chemotherapy infusion of ambulatory head and neck cancer patients
1982
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
2002
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review
1994
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
1993
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer
1995
A Population-Based Study of Patterns of Care for Ovarian Cancer: Who Is Seen by a Gynecologic Oncologist and Who Is Not?
2002
Testicular Germ-Cell Cancer
1997 Standout
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives
1989
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Ovarian cancer
2014 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Meta-analysis of surgery in advanced ovarian carcinoma: Ismaximum cytoreductive surgery an independent determinant of prognosis?
1992
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy.
1988
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
1995
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
1987
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Head and neck cancer
2008 Standout
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
1998
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma
1995
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
1988
When Checkpoints Fail
1997 StandoutNobel
Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the princess margaret hospital experience
1991
Nasopharyngeal carcinoma
2019 Standout
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
2004
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospective Study
1998
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
1997
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer
2000
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
1989
Management of head and neck cancer
1994
Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
2004
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
1990
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Carboplatin: current status and future prospects
1988
Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance
2001
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Head and Neck Cancer
1993 Standout
End points for new agents in induction chemotherapy for locally advanced head and neck cancers
2002
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphaide therapy in advanced ovarian adenocarcinoma
1994
Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model
1989
High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
1990
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: A phase I–II study
1989
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
A Massive Outbreak in Milwaukee of Cryptosporidium Infection Transmitted through the Public Water Supply
1994 Standout
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
1992
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials.
1996
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
1989
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
A phase II trial of 10-Ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck
1992
Head and Neck Cancer
2001 Standout
A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer
2000
Cancer of the Ovary
2004 Standout
Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer
1984
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Synthesis of Novel gluco‐ and galacto‐Functionalized Platinum Complexes
2009
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Changing role of chemotherapy in treatment of head and neck cancer
1982
A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II
1979
Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity
1986
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
1998
Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules
1981
Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin
1985
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
1986 Standout
Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach
1988 Standout
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
1986
Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based Regimens
2002
Advanced Ovarian Cancer: Long-Term Results of Treatment with Intensive Cisplatin-Based Chemotherapy of Brief Duration
1988
Innovative Regional Therapy for Head and Neck Cancer
1982
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
2001
Pathology of surgery after induction chemotherapy: an analysis of resectability and locoregional control
1986
Intraperitoneal therapy in the management of ovarian carcinoma.
1990
Randomized clinical trial of mitomycin c as an adjunct to radiotherapy in head and neck cancer
1989
Cryptosporidiosis: Clinical, Epidemiologic, and Parasitologic Review
1984
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Intestinal operations in patients with ovarian carcinoma
1981
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma
1981
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
2006
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
2000
Formation of Glyco-Functionalized Platinum Complexes by Cross-Metathesis and Evaluation of Their Efficacy in Inhibition of Lung Tumor Cell Lines
2012
Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based Regimens
2002
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2004 Standout
Immunobiologic Aspects of Head and Neck Cancer: Clinical and Laboratory Correlates
1991
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
1994 StandoutNobel
A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck
1983
Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer
1991 Standout
Mechanism of action of hydroxyurea.
1992
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
1986
Randomized trial of conventional versus high fractional dose radiation therapy in the treatment of advanced head and neck cancer
1982
Cisplatin
1984 Standout
Works of Steven E. Vogl being referenced
Fatal Cryptosporidiosis Complicating Kaposi’s Sarcoma in an Immunocompromised Man
1984
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy
1990
Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group
1992
Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
1991
Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
1982
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878
1996
MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung.Low response rate in a cooperative group study
1979
Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck
1982
Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens
1983
“Second-effort” surgical resection for bulky ovarian cancer
1984
Carboplatin in advanced, refractory germ cell neoplasms: a phase II Eastern Cooperative Oncology Group Study.
1987
Ovarian Cancer
1979
A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer
1985
Effective chemotherapy for esophageal cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II
1981
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
1986
Failure of effective initial chemotherapy to modify the course of stage IV (MO) squamous cancer of the head and neck
1982
Is there cumulative or delayed toxicity from Cis-platinum?
1983
Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity
1983
Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule
1979
Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent
1985
Combination chemotherapy with adriamycin andcis-diamminedichloroplatinum in patients with neoplastic diseases
1976
Toxicity of Cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration
1980